PA
TGTX icon

PSI Advisors’s TG Therapeutics TGTX Stock Holding History

PSI Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-700
Closed -$21.1K – 932
2024
Q4 		$21.1K Hold
700
– – 0.01% 415
2024
Q3 		$16.4K Sell
700
-500
-42% -$10.9K ﹤0.01% 455
2024
Q2 		$21.3K Buy
1,200
+1,000
+500% +$16K 0.01% 392
2024
Q1 		$3.04K Sell
200
-1,000
-83% -$15.9K ﹤0.01% 642
2023
Q4 		$20.5K Sell
1,200
-75
-6% -$872 0.01% 411
2023
Q3 		$10.7K Hold
1,275
– – ﹤0.01% 478
2023
Q2 		$31.7K Hold
1,275
– – 0.01% 315
2023
Q1 		$19.2K Hold
1,275
– – 0.01% 340
2022
Q4 		$15.1K Hold
1,275
– – 0.01% 367
2022
Q3 		$8K Hold
1,275
– – ﹤0.01% 469
2022
Q2 		$5K Buy
1,275
+1,000
+364% +$6.24K ﹤0.01% 579
2022
Q1 		$3K Sell
275
-1,000
-78% -$11.6K ﹤0.01% 603
2021
Q4 		$24K Sell
1,275
-825
-39% -$21.4K 0.01% 374
2021
Q3 		$70K Buy
+2,100
New +$65K 0.03% 242

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PSI Advisors's TGTX Position: Q1 2025 in Review

PSI Advisors sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 700 shares — an estimated $21.1K sold.

PSI Advisors first reported a position in TGTX in Q3 2021 and held it in 14 quarters. The position peaked at $70K in Q3 2021. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • PSI Advisors reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PSI Advisors sold 700 TG Therapeutics shares in Q1 2025, an estimated $21.1K.
  • PSI Advisors first reported a position in TG Therapeutics in Q3 2021 and held it in 14 quarters.
  • PSI Advisors's TG Therapeutics position peaked at $70K in Q3 2021.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on PSI Advisors's 13F filing for Q1 2025, filed 21 Apr 2025.